Cargando…
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
The tumor biology targeted therapies have improved outcomes in colorectal cancer (CRC). The epidermal growth factor receptor (EGFR) inhibitors represent one of these successful strategies. EGFR is frequently overexpressed in CRCs and associated with a malignant phenotype. Two EGFR inhibitors have sh...
Autores principales: | Williams, Kerry J, Lockhart, A Craig |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886332/ https://www.ncbi.nlm.nih.gov/pubmed/20616903 |
Ejemplares similares
-
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
por: Hoda, Daanish, et al.
Publicado: (2008) -
Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: Kim, George P, et al.
Publicado: (2008) -
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
por: Ketzer, Sander, et al.
Publicado: (2017) -
Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report
por: Kamo, Hitomi, et al.
Publicado: (2019) -
Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)